DK1436397T3 - Hepatitis C virus vaccine - Google Patents

Hepatitis C virus vaccine

Info

Publication number
DK1436397T3
DK1436397T3 DK02773740.2T DK02773740T DK1436397T3 DK 1436397 T3 DK1436397 T3 DK 1436397T3 DK 02773740 T DK02773740 T DK 02773740T DK 1436397 T3 DK1436397 T3 DK 1436397T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
hepatitis
virus vaccine
ns5b
hcv
Prior art date
Application number
DK02773740.2T
Other languages
Danish (da)
English (en)
Inventor
Emilio A Emini
David C Kaslow
Andrew J Bett
Alfredo Nicosia
Armin Lahm
Alessandra Luzzago
Riccardo Cortese
Stefano Colloca
John W Shiver
Original Assignee
Merck Sharp & Dohme
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Angeletti P Ist Richerche Bio filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK1436397T3 publication Critical patent/DK1436397T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK02773740.2T 2001-10-11 2002-10-10 Hepatitis C virus vaccine DK1436397T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32865501P 2001-10-11 2001-10-11
US36377402P 2002-03-13 2002-03-13
PCT/US2002/032512 WO2003031588A2 (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine

Publications (1)

Publication Number Publication Date
DK1436397T3 true DK1436397T3 (da) 2010-08-09

Family

ID=42828995

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02773740.2T DK1436397T3 (da) 2001-10-11 2002-10-10 Hepatitis C virus vaccine

Country Status (9)

Country Link
US (3) US7598362B2 (enExample)
EP (1) EP1436397B1 (enExample)
JP (1) JP4475561B2 (enExample)
CN (1) CN1582337B (enExample)
AT (1) ATE467680T1 (enExample)
AU (1) AU2002337840B2 (enExample)
CA (1) CA2461380C (enExample)
DK (1) DK1436397T3 (enExample)
WO (1) WO2003031588A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
AU2001290178A1 (en) 2000-08-17 2002-02-25 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP2172552A3 (en) * 2001-10-11 2010-07-21 Merck Sharp & Dohme Corp. Recombinant nucleic acids comprising regions of AD6
JP4475561B2 (ja) * 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスワクチン
JP2008518591A (ja) * 2004-11-02 2008-06-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 複製欠損アデノウイルスベクターの製造のためのアデノウイルスアンプリコンおよびプロデューサー細胞、その製造方法および用途
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
US7951531B2 (en) * 2005-02-17 2011-05-31 University Of Iowa Research Foundation Flavivirus NS5A proteins for the treatment of HIV
DE102005015005A1 (de) * 2005-04-01 2006-10-05 Qiagen Gmbh Verfahren zur Behandlung einer Biomoleküle enthaltenden Probe
EP1888751A2 (en) 2005-05-25 2008-02-20 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
EP1893636A2 (en) * 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
CN1887350B (zh) * 2005-06-28 2010-10-06 深圳市源兴生物医药科技有限公司 一种重组疫苗及其用途
AU2006315026B2 (en) * 2005-11-21 2012-11-22 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
EP2076531B1 (en) * 2006-10-12 2011-11-23 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
WO2008140632A2 (en) 2007-01-24 2008-11-20 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus epidermidis
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
CN101663399B (zh) * 2007-12-18 2013-01-02 北京大学人民医院 一种抗hcv的疫苗及其制备方法和用途
WO2010014567A2 (en) * 2008-08-01 2010-02-04 Merck & Co., Inc. Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
US8829174B2 (en) 2008-10-29 2014-09-09 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
CN102292104A (zh) 2008-11-26 2011-12-21 默沙东公司 用于诱导抗金黄色葡萄球菌的保护性免疫应答的多肽
MX2011005578A (es) 2008-11-26 2011-06-30 Merck Sharp & Dohme Polipeptidos para inducir una respuesta inmune protectora contra staphylococcus aureus.
MX2011007980A (es) 2009-02-02 2011-08-17 Okairos Ag Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
CN102645534B (zh) * 2012-04-26 2015-08-12 杭州市萧山区第一人民医院 基于量子点编码微球芯片检测丙型肝炎病毒的方法
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
US20180000926A1 (en) * 2015-01-15 2018-01-04 Babita Agrawal Methods of inducing an immune response to hepatitis c virus
CN108277230A (zh) * 2018-02-07 2018-07-13 华中科技大学 一种融合dna及其制备的疫苗

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5747339A (en) 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
EP0933426A1 (en) * 1990-06-25 1999-08-04 The Research Foundation for Microbial Diseases of Osaka University Non-a, non-b hepatitis virus genomic cdna fragments and antigen polypeptides
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US6140087A (en) * 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5731172A (en) * 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
JP2002500502A (ja) * 1996-06-11 2002-01-08 メルク エンド カンパニー インコーポレーテッド 合成ｃ型肝炎遺伝子
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
EP0981606A2 (en) 1997-05-12 2000-03-01 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method and construct for inhibition of cell migration
US6221646B1 (en) * 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
KR20060057653A (ko) 1998-01-30 2006-05-26 더 제너럴 하스피탈 코포레이션 Ｃ형 간염 바이러스의 비구조 단백질을 이용한 유전자면역법
CA2328180A1 (en) 1998-04-14 1999-10-21 Merck & Co., Inc. Needleless administration of polynucleotide formulations
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
US6156588A (en) 1998-06-23 2000-12-05 Vlsi Technology, Inc. Method of forming anti-fuse structure
EP1108048A1 (en) 1998-08-24 2001-06-20 Genzyme Corporation Cationic complexes of polymer-modified adenovirus
CA2359795A1 (en) 1999-01-14 2000-07-20 Novartis Ag Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE
US6627190B2 (en) * 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
US6511832B1 (en) * 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
EP1233982B1 (en) 1999-11-24 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Novel hcv non-structural polypeptide
DE60040755D1 (de) 1999-12-01 2008-12-18 Novartis Vaccines & Diagnostic Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CA2422882A1 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
JP4475561B2 (ja) * 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスワクチン

Also Published As

Publication number Publication date
CA2461380A1 (en) 2003-04-17
US20090233992A1 (en) 2009-09-17
US7598362B2 (en) 2009-10-06
US20100129901A1 (en) 2010-05-27
AU2002337840B2 (en) 2007-08-09
CA2461380C (en) 2011-03-22
ATE467680T1 (de) 2010-05-15
US8530234B2 (en) 2013-09-10
JP2005505286A (ja) 2005-02-24
WO2003031588A2 (en) 2003-04-17
EP1436397B1 (en) 2010-05-12
CN1582337B (zh) 2011-12-14
JP4475561B2 (ja) 2010-06-09
CN1582337A (zh) 2005-02-16
EP1436397A2 (en) 2004-07-14
WO2003031588A3 (en) 2003-10-30
US20040247615A1 (en) 2004-12-09
US8142794B2 (en) 2012-03-27
EP1436397A4 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
ATE467680T1 (de) Hepatitis-c-virus-impfstoff
Zhong et al. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase
Weiner et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity
Tanaka et al. Structure of the 3'terminus of the hepatitis C virus genome
Friebe et al. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication
ATE258227T1 (de) Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv)
Wood et al. Hepatitis C virus 3′ X region interacts with human ribosomal proteins
EP1256628A3 (en) Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
EP1227161A3 (en) Primers, probes and methods for the detection of nucleic acids of hepatitis C viruses
Wyatt et al. Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection
DK0783321T3 (da) VR-2332 viral nucleotidsekvens og fremgangsmåder til anvendelse
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
DK1026262T3 (da) Oligonukleotidprimere til effektiv detektering af hepatitis C-virus (HCV) og fremgangsmåder til anvendelse deraf
DK1629091T3 (da) Præparat indeholdende polyproteinet NS3/NS4 og polypeptidet NS5B af HCV, ekspressionsvektorer omfattende tilsvarende nukleinsyresekvenser og terapeutisk anvendelse deraf
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
ES2094744T3 (es) Manipulaciones geneticas con el adn recombinante que contiene secuencias derivadas de los virus arn.
DK0698216T4 (da) Fremgangsmåder til typebestemmelse af hepatitis-C-virus og anvendte reagenser heri
DK1412505T3 (da) DNA-sekvenser til regulering af transkription
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
Butkiewicz et al. Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
Waris et al. Two-step affinity purification of the hepatitis C virus ribonucleoprotein complex
DE60034884D1 (de) Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen
CR7651A (es) Identificacion de oligonucleotidos para la captura, deteccion y cuantificacion de acidos virales nucleicos de hepatitis a
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof